Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.62 |
| ▸ | IDO1 | P14902 | 15/20 | 0.59 |
| ▸ | AGXT | P21549 | 11/20 | 0.59 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6876851 | 0.81 | ADRB2 (0.58) | ADRB2IDO1AGXTCLK4 | |
| SCHEMBL25735768 | 0.80 | CLK4 (0.57) | ADRB2CLK4 | |
| SCHEMBL23961939 | 0.79 | IDO1 (0.58) | IDO1AGXTCYP3A4 | |
| SCHEMBL6875904 | 0.77 | ADRB2 (0.53) | ADRB2IDO1AGXTCLK4 | |
| SCHEMBL2427481 | 0.77 | ADRB2 (1.00) | ADRB2CLK4 | |
| SCHEMBL6875901 | 0.76 | ADRB2 (0.52) | ADRB2IDO1AGXTCLK4 | |
| SCHEMBL28135249 | 0.75 | ADRB2 (0.96) | ADRB2CLK4 | |
| SCHEMBL6685962 | 0.75 | CLK4 (0.64) | ADRB2CLK4CYP3A4 | |
| SCHEMBL438248 | 0.75 | IDO1 (0.78) | IDO1AGXTCYP3A4 | |
| SCHEMBL1714754 | 0.74 | IDO1 (1.00) | IDO1AGXTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825170-B2 | ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220272-A1 | 6-O-acyl ketolide antibacterials | Q6ZSR9, ACSL6, RPS4Y1 | ADRB2 4390/4885IDO1 1322/4885AGXT 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.